Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Opinions on the Review of the NHI Pricing Rule (Excerpt) Presented by the FPMAJ
June 15, 2009
- More Drugs Granted Premiums: Mr Nakagaki
June 15, 2009
- Sandoz's Somatropin to Be Approved as 1st Biosimilar Based on New Guidance
June 15, 2009
- R&D NEWS IN BRIEF
June 8, 2009
- Chuikyo Subcommittee to Review Whether Price Gaps Promote Use of Generics
June 8, 2009
- Sleep Disorders Increase Risk of Other Diseases
June 8, 2009
- Sawai: Sales, Profits Up Driven by Gov't Policy to Promote Use of Generics
June 8, 2009
- Only 20% of Mothers Talk to Daughters about GYN Diseases
June 8, 2009
- Publicity on RLS Essential for Patients, Physicians
June 8, 2009
- REGULATORY NEWS IN BRIEF
June 8, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 8, 2009
- Atul Sobti Named CEO of Ranbaxy
June 8, 2009
- NBI's Sales Exceeded Industry Average for Five Consecutive Years: Dr T. Heil
June 8, 2009
- Towa: New Products Listed in 2008 Drive Sales
June 8, 2009
- Takeda Licenses Hib Vaccine from Novartis
June 8, 2009
- Nichi-Iko to Create Joint Venture with Mitani Sangyo to Manufacture Raw Materials for Generics
June 8, 2009
- Daiichi Sankyo Revises Net Loss from ¥335.8 Bil. to ¥215.5 Bil.
June 8, 2009
- Korosho to Call For Stricter Adherence to Ryotan-kisoku for Use of More Generics
June 8, 2009
- Co-DIO, Ecard Ranked No. 1 and 2 on Both GP and HP Markets
June 8, 2009
- Rohto: Sales Up 16th Year in a Row
June 8, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…